Peptide Directory

Weight Management

Semaglutide

Semaglutide: understand product-specific approved uses, weight-loss trial results, important safety warnings, and questions for your prescriber.

At a glance

Semaglutide: understand product-specific approved uses, weight-loss trial results, important safety warnings, and questions for your prescriber.

What is semaglutide?

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It affects appetite and food intake, slows gastric emptying, and influences glucose regulation. These effects do not make every semaglutide product appropriate for every patient.

This article focuses on the evidence and labeling for Wegovy injection. The active ingredient name alone is not a prescribing instruction: product, formulation, indication, age and medical history matter. An approved branded medicine and an unapproved compounded product should not be treated as interchangeable.

Sources: [wegovy-label]

Approved uses depend on the product

The cited Wegovy injection label covers long-term weight reduction in adults and adolescents aged 12 years and older with obesity, and in adults with overweight plus at least one weight-related condition, alongside a reduced-calorie diet and increased physical activity.

It also covers reduction of major cardiovascular events in adults with established cardiovascular disease and overweight or obesity. This is not a claim that everyone taking semaglutide receives the same cardiovascular benefit.

The August 2025 label includes adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and moderate-to-advanced fibrosis, stages F2–F3. That indication received accelerated approval based on improvement in MASH and fibrosis, with confirmation of clinical benefit still required. Consult the current product label rather than assuming these uses apply to all formulations.

Sources: [wegovy-label]

What the STEP 1 trial found

STEP 1 enrolled 1,961 adults with obesity or overweight and a weight-related condition who did not have diabetes. Participants received semaglutide or placebo, with lifestyle intervention, for 68 weeks.

Average body-weight change was −14.9% with semaglutide versus −2.4% with placebo. These are group averages, not a promised result for an individual. Nausea and diarrhea were common; gastrointestinal events caused treatment discontinuation in 4.5% of the semaglutide group versus 0.8% of the placebo group.

The trial was funded by Novo Nordisk. Its population, product and treatment plan matter when interpreting the results. Do not extrapolate the average to every patient, to an unapproved formulation, or to unsupervised use.

Sources: [step-1]

Important safety and interaction considerations

Wegovy carries a boxed warning about thyroid C-cell tumors seen in rodents; whether it causes these tumors in humans is unknown. It is contraindicated with a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or hypersensitivity to the product.

Common effects include nausea, vomiting, diarrhea, constipation and abdominal pain. Important warnings include pancreatitis, gallbladder disease, severe gastrointestinal reactions, kidney injury related to fluid loss, and diabetic retinopathy complications. The label does not recommend use in severe gastroparesis.

Insulin and insulin secretagogues can increase hypoglycemia risk when used with semaglutide. Delayed gastric emptying can affect oral medicines. Tell the prescriber about all medicines and planned anesthesia or deep sedation, and discuss pregnancy plans before treatment. The label advises against combining Wegovy with other semaglutide products or other GLP-1 receptor agonists.

This is not the full safety label. Seek urgent medical care for a severe allergic reaction or severe persistent abdominal pain, and contact the prescribing team about significant side effects rather than changing doses based on an online guide.

Sources: [wegovy-label]

Prescribing and product-quality questions

Wegovy injection is administered weekly and its dose is increased according to product-specific instructions and tolerability. This article does not provide a personal dosing schedule. Other semaglutide formulations have different directions; use the prescription and current label for the exact product.

FDA warns about unapproved GLP-1 products, including dosing errors and semaglutide salt forms that differ from the active ingredient in approved drugs. Ask what product is being dispensed, why it was chosen, what follow-up is planned, and what to do if side effects or missed doses occur.

Sources: [wegovy-label] [compounding]

Frequently asked questions

These FAQs use the sources listed below. They are not independently clinically reviewed.

How much weight can I lose with semaglutide?

STEP 1 found an average 14.9% reduction at 68 weeks with semaglutide versus 2.4% with placebo, both with lifestyle intervention, in adults without diabetes. Individual results vary; this is not a guarantee.

Sources: [step-1]

How is semaglutide administered?

Wegovy injection is given under the skin once weekly, with product-specific dose escalation. This does not describe every semaglutide formulation. Follow the exact prescription and label rather than an online dosing protocol.

Sources: [wegovy-label]

Is semaglutide safe long-term?

Approved products have been evaluated for specified uses, but approval does not mean risk-free treatment. Ongoing follow-up should address side effects, interactions and whether treatment remains appropriate. The duration and population of each study limit what it tells us.

Sources: [wegovy-label] [step-1]

Sources and reading notes

Sources support the cited sections or FAQs, not every statement in a legacy overview. A source link is not an endorsement of a product or treatment.

About this entry

Article updated: .

AI-assisted source synthesis prepared for Peptide Directory. No independent clinical review has been performed.